164 results on '"Forconi, Francesco"'
Search Results
2. XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression
3. Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL
4. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
5. The essential microenvironmental role of oligomannoses specifically inserted into the antigen-binding sites of lymphoma cells
6. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
7. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
8. Mutations in the IgG B cell receptor associated with class-switched B cell lymphomas
9. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
10. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment
11. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
12. Proliferative History Is a Novel Driver of Clinical Outcome in Splenic Marginal Zone Lymphoma
13. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells
14. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
15. The essential microenvironmental role of oligomannoses inserted into the antigen-binding sites of lymphoma cells
16. DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity
17. Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia
18. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
19. PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
20. S142: FOXO1-RICTOR AXIS INDUCES ADAPTIVE INCREASE IN AKT ACTIVITY DURING BCR INHIBITOR THERAPY IN CLL: IMPLICATIONS FOR COMBINATION THERAPY
21. PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
22. Hairy cell leukemia variant and WHO classification correspondence Re: 5thedition WHO classification haematolymphoid tumors: lymphoid neoplasms
23. BCL2 Inhibition in Refractory Hairy-Cell Leukemia
24. Supplementary methods and Figures from The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
25. Supplementary Figure 1 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
26. Supplementary Table 4 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
27. Supplementary Figure 2 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
28. Supplementary Tables 1-3 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
29. Supplementary Table 6 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
30. Supplementary Table 5 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
31. Supplementary Tables S1-S4 from The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
32. Supplementary Data from Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome
33. Data from STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy
34. Supplementary Data from Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells
35. Supplementary Table 7 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
36. CCR Translation for this Article from Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features
37. Supplemetary data from STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy
38. Supplementary Data from Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features
39. Supplementary Tables and Figures from Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients
40. MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
41. Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
42. DC-SIGN Binding to the Oligomannose-Type Glycans on the Surface Immunoglobulin Variable Region of Follicular Lymphoma Promotes Selective Adhesion to Microenvironmental VCAM-1
43. EMT-like Activation in CLL Provides Novel Therapeutic Target
44. Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia
45. Development of a distributed international patient data registry for hairy cell leukemia
46. BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells
47. KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity
48. CLL-638 Latest Results From an Ongoing Firstin-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies
49. Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies
50. TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.